Indium In 111-DOTA-Daratumumab

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameIndium In 111-DOTA-Daratumumab
Drug Alias Name111Indium labeled daratumumab111Indium-DOTA-Daratumumab111In-DOTA-daratumumab[111In]-DOTA-Daratumumab111In-Daratumumab +[6] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate +[4] 
Mechanisms of ActionLymphocyte differentiation antigen CD38 inhibitors
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsMyelodysplastic SyndromesMultiple MyelomaLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesMultiple MyelomaLeukemia, Myeloid, Acute +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A